BioSpace News Archive

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in the phase 3 pivotal trial (TALLER) for eftansomatropin alfa (also known as TJ101) as a weekly treatment for pediatric growth hormone deficiency (PGHD) in China

Despite the continued COVID-19 pandemic, cancer screening remains a public health priority. Existing disparities will likely increase without deliberate focus to address known barriers to cancer screening along with additional challenges related to the pandemic.

AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, today announced the completion of a Phase 1 clinical study in Indonesia of its personalized vaccine candidate, AV-COVID-19, for the novel coronavirus (SARS-CoV-2).

Castlight Health, Inc., a leader in healthcare navigation, announced that Maeve O’Meara, chief executive officer, and Will Bondurant, chief financial officer, will participate in the Cowen 41st Annual Health Care Conference, including a fireside chat on Thursday, March 4, 2021 at 10:30 am ET.

Kindred Biosciences, Inc., a biopharmaceutical company focused on saving and improving the lives of pets, announced that it has submitted efficacy data to support the prophylactic indication for KIND-030 to the United States Department of Agriculture Center for Veterinary Biologics for review.

The new NKF Patient Network will help improve the lives of people with kidney disease through research, clinical care, drug development, and supportive health policy decisions

Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare management company, today announced that Kenneth Sim, M.D., Executive Chairman and Co-Chief Executive Officer of ApolloMed

MedX Health Corp. is pleased to announce that it has closed on the final $1.4 million of the $4 million Non-brokered Private Placement of 80 Convertible Debenture Loan Notes, each with a face value of $50,000, as originally announced in its Press Release dated January 25, 2021.

ChemoCentryx, Inc., announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:.

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, announced today that the Company will present at the 2021 H.C. Wainwright Global Life Sciences Conference, scheduled for March 9 – 10.